PL2948179T3 - Kompozycje zawierające nanocząstki tlenku hafnu(iv) lub tlenku renu(iv) w połączeniu z promieniowaniem jonizującym do leczenia nowotworu - Google Patents

Kompozycje zawierające nanocząstki tlenku hafnu(iv) lub tlenku renu(iv) w połączeniu z promieniowaniem jonizującym do leczenia nowotworu

Info

Publication number: PL2948179T3
Authority: PL; Poland
Prior art keywords: oxide; nanopatis; rene; cancer; treatment
Prior art date: 2013-01-25

Application number

PL14701965T

Other languages

English (en)

Inventor

Elsa Borghi

Laurent Levy

Agnès Pottier

Original Assignee

Nanobiotix

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-01-25

Filing date

2014-01-24

Publication date

2019-10-31

2014-01-24 Application filed by Nanobiotix filed Critical Nanobiotix

2019-10-31 Publication of PL2948179T3 publication Critical patent/PL2948179T3/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1085—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy characterised by the type of particles applied to the patient
- A61N2005/1087—Ions; Protons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1085—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy characterised by the type of particles applied to the patient
- A61N2005/1089—Electrons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Nanotechnology (AREA)
Medical Informatics (AREA)
Molecular Biology (AREA)
Crystallography & Structural Chemistry (AREA)
Biophysics (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Dermatology (AREA)
Inorganic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

PL14701965T 2013-01-25 2014-01-24 Kompozycje zawierające nanocząstki tlenku hafnu(iv) lub tlenku renu(iv) w połączeniu z promieniowaniem jonizującym do leczenia nowotworu PL2948179T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201361756533P	2013-01-25	2013-01-25
EP13305087		2013-01-25
EP14701965.7A EP2948179B1 (en)	2013-01-25	2014-01-24	Compositions comprising nanoparticles of hafnium (iv) oxide or rhenium (iv) oxide in combination with ionizing radiations for treating cancer
PCT/EP2014/051367 WO2014114732A1 (en)	2013-01-25	2014-01-24	Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer

Publications (1)

Publication Number	Publication Date
PL2948179T3 true PL2948179T3 (pl)	2019-10-31

Family

ID=47710064

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL14701965T PL2948179T3 (pl)	2013-01-25	2014-01-24	Kompozycje zawierające nanocząstki tlenku hafnu(iv) lub tlenku renu(iv) w połączeniu z promieniowaniem jonizującym do leczenia nowotworu

Country Status (22)

Country	Link
US (4)	US10098952B2 (pl)
EP (1)	EP2948179B1 (pl)
JP (2)	JP6619231B2 (pl)
KR (2)	KR102385193B1 (pl)
CN (1)	CN105120897B (pl)
AR (1)	AR094577A1 (pl)
AU (1)	AU2014209899B2 (pl)
BR (1)	BR112015017490A2 (pl)
CA (3)	CA2897362C (pl)
CY (1)	CY1121838T1 (pl)
EA (1)	EA034242B1 (pl)
IL (1)	IL239767B (pl)
MA (1)	MA38318A1 (pl)
MX (1)	MX369664B (pl)
PL (1)	PL2948179T3 (pl)
RS (1)	RS59042B1 (pl)
SG (1)	SG11201505277VA (pl)
SI (1)	SI2948179T1 (pl)
TW (1)	TW201442726A (pl)
UA (1)	UA116007C2 (pl)
WO (1)	WO2014114732A1 (pl)
ZA (1)	ZA201505510B (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP6042450B2 (ja)	2011-12-16	2016-12-14	ナノビオティックスＮａｎｏｂｉｏｔｉｘ	金属材料および酸化ハフニウム材料を含むナノ粒子、その製造および使用
PL2948179T3 (pl)	2013-01-25	2019-10-31	Nanobiotix	Kompozycje zawierające nanocząstki tlenku hafnu(iv) lub tlenku renu(iv) w połączeniu z promieniowaniem jonizującym do leczenia nowotworu
WO2015102680A2 (en)	2013-09-11	2015-07-09	The Board Of Trustees Of The Leland Stanford Junior University	Methods and systems for beam intensity-modulation to facilitate rapid radiation therapies
EP2886128A1 (en) *	2013-12-20	2015-06-24	Nanobiotix	Pharmaceutical composition comprising nanoparticles, preparation and uses thereof
JP2018516256A (ja)	2015-05-28	2018-06-21	ナノビオティックスＮａｎｏｂｉｏｔｉｘ	治療用ワクチンとしての使用のためのナノ粒子
US11247054B2 (en) *	2016-12-21	2022-02-15	Nanobiotix S.A.	Nanoparticles for use for enhancing brain performances or for treating stress
AU2017384425B2 (en) *	2016-12-21	2023-08-31	Nanobiotix	Nanoparticles for use for treating a neuronal disorder
EP3424533A1 (en) *	2017-07-05	2019-01-09	Nh Theraguix	Methods for treating tumors
US11173325B2 (en)	2017-07-21	2021-11-16	Varian Medical Systems, Inc.	Methods of use of ultra-high dose rate radiation and therapeutic agent
JP2022540652A (ja)	2019-07-12	2022-09-16	オレゴンヘルスアンドサイエンスユニバーシティ	分裂期キナーゼ阻害剤と免疫チェックポイント阻害剤との同時送達のための治療用構築物
US20220249389A1 (en) *	2019-07-12	2022-08-11	Oregon Health & Science University	Immunotherapeutic constructs and methods of their use
EP4141110A4 (en)	2020-04-24	2025-04-09	Sf Biotech Laboratuvar Danismanlik Anonim Sirketi	Method for producing particles of bacteriophages of the genus levivirus
FR3160407A1 (fr)	2024-03-25	2025-09-26	Gcs Institut De Cancerologie Strasbourg Europe	Complexe peptidique radiosensibilisant

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000006244A2 (en) *	1998-07-30	2000-02-10	Hainfeld James F	Loading metal particles into cell membrane vesicles and metal particle use for imaging and therapy
AU2002218087A1 (en) *	2000-11-20	2002-05-27	Oncolytics Biotech Inc.	Method for optimally delivering virus to a solid tumor mass
US6756063B2 (en) *	2001-03-29	2004-06-29	Zoltan Laboratories, Llc	Methods and compositions for the treatment of human and animal cancers
FR2884149B1 (fr) *	2005-04-12	2007-06-08	Henri Mehier	Tube implantable destine a l'injection notamment de fluide caloporteur dans tout ou partie d'un tissu humain ou animal
EP1852107A1 (en)	2006-04-19	2007-11-07	Nanobiotix	Magnetic nanoparticles compositions and uses thereof
EP2130553A1 (en) *	2008-06-05	2009-12-09	Nanobiotix	Inorganic nanoparticles of high density to destroy cells in-vivo
US8395131B2 (en) *	2009-06-20	2013-03-12	Xiaodong Wu	Method for three dimensional (3D) lattice radiotherapy
EP2275137A1 (en)	2009-07-10	2011-01-19	Nanobiotix	Metallic nanoparticles, preparation and uses thereof
US20130225901A1 (en)	2010-04-05	2013-08-29	Nanospectra Biosciences, Inc.	Enhancement of radiation therapy by targeted high-z nanoparticles
EP2670393B8 (en)	2011-01-31	2016-10-05	Nanobiotix	Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles.
CN103429227B (zh)	2011-01-31	2017-12-19	纳米生物技术公司	纳米粒子递送系统、其制备及应用
JP6042450B2 (ja)	2011-12-16	2016-12-14	ナノビオティックスＮａｎｏｂｉｏｔｉｘ	金属材料および酸化ハフニウム材料を含むナノ粒子、その製造および使用
PL2948179T3 (pl)	2013-01-25	2019-10-31	Nanobiotix	Kompozycje zawierające nanocząstki tlenku hafnu(iv) lub tlenku renu(iv) w połączeniu z promieniowaniem jonizującym do leczenia nowotworu
MA38687A1 (fr)	2013-05-30	2017-12-29	Nanobiotix	Composition pharmaceutique, préparation et utilisations de celle-ci
WO2014202738A1 (en)	2013-06-20	2014-12-24	Nanobiotix	Compositions and methods for use in oncology
AU2014283217A1 (en)	2013-06-20	2015-12-24	Nanobiotix	Compositions and methods for use in medical diagnosis
UA124448C2 (uk)	2013-06-20	2021-09-22	Нанобіотікс	Спосіб лікування раку у суб’єкта за допомогою біологічно сумісного гелю, що містить нанонастинки та/або їх агрегати, набір та його застосування
EP2886128A1 (en)	2013-12-20	2015-06-24	Nanobiotix	Pharmaceutical composition comprising nanoparticles, preparation and uses thereof
PL3229843T3 (pl)	2014-11-25	2020-06-29	Curadigm Sas	Kompozycja farmaceutyczna, wytwarzanie i zastosowanie tej kompozycji
PT3229776T (pt)	2014-11-25	2023-08-17	Curadigm Sas	Composição farmacêutica combinando pelo menos duas nanopartícuas distintas e um composto farmacêutico, preparaçâo e suas utilizações
AU2015352685B2 (en)	2014-11-25	2020-09-17	Nanobiotix	Pharmaceutical composition, preparation and uses thereof
WO2016083336A1 (en)	2014-11-25	2016-06-02	Nanobiotix	Pharmaceutical composition, preparation and uses thereof
DK3223796T3 (da)	2014-11-25	2021-09-27	Curadigm Sas	Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
JP2018516256A (ja)	2015-05-28	2018-06-21	ナノビオティックスＮａｎｏｂｉｏｔｉｘ	治療用ワクチンとしての使用のためのナノ粒子
AU2017384425B2 (en)	2016-12-21	2023-08-31	Nanobiotix	Nanoparticles for use for treating a neuronal disorder
AU2017384538A1 (en)	2016-12-21	2019-08-01	Nanobiotix	Coated nanoparticles for use for modulating electrical polarization of neurons
US11247054B2 (en)	2016-12-21	2022-02-15	Nanobiotix S.A.	Nanoparticles for use for enhancing brain performances or for treating stress
PT3727402T (pt)	2017-12-19	2024-11-07	Nanobiotix	Nanopartículas para utilização na melhoria dos desempenhos cerebrais ou no tratamento do stress
CN111886004A (zh)	2017-12-19	2020-11-03	纳米生物技术公司	用于治疗神经元障碍的纳米粒子
EP4157457A1 (en)	2020-05-26	2023-04-05	Nanobiotix	Nanoparticles, ionizing radiation and innovative therapeutic combinations thereof

2014
- 2014-01-24 PL PL14701965T patent/PL2948179T3/pl unknown
- 2014-01-24 US US14/762,971 patent/US10098952B2/en active Active
- 2014-01-24 EP EP14701965.7A patent/EP2948179B1/en active Active
- 2014-01-24 WO PCT/EP2014/051367 patent/WO2014114732A1/en not_active Ceased
- 2014-01-24 UA UAA201508289A patent/UA116007C2/uk unknown
- 2014-01-24 RS RS20190848A patent/RS59042B1/sr unknown
- 2014-01-24 AR ARP140100222A patent/AR094577A1/es unknown
- 2014-01-24 JP JP2015554149A patent/JP6619231B2/ja active Active
- 2014-01-24 CA CA2897362A patent/CA2897362C/en active Active
- 2014-01-24 KR KR1020217006350A patent/KR102385193B1/ko active Active
- 2014-01-24 SG SG11201505277VA patent/SG11201505277VA/en unknown
- 2014-01-24 KR KR1020157022940A patent/KR102225239B1/ko active Active
- 2014-01-24 MA MA38318A patent/MA38318A1/fr unknown
- 2014-01-24 CA CA3179586A patent/CA3179586C/en active Active
- 2014-01-24 MX MX2015009409A patent/MX369664B/es active IP Right Grant
- 2014-01-24 BR BR112015017490A patent/BR112015017490A2/pt not_active Application Discontinuation
- 2014-01-24 CN CN201480006025.0A patent/CN105120897B/zh active Active
- 2014-01-24 CA CA3251146A patent/CA3251146A1/en active Pending
- 2014-01-24 TW TW103102786A patent/TW201442726A/zh unknown
- 2014-01-24 EA EA201591378A patent/EA034242B1/ru not_active IP Right Cessation
- 2014-01-24 AU AU2014209899A patent/AU2014209899B2/en active Active
- 2014-01-24 SI SI201431254T patent/SI2948179T1/sl unknown
2015
- 2015-07-02 IL IL239767A patent/IL239767B/en active IP Right Grant
- 2015-07-31 ZA ZA2015/05510A patent/ZA201505510B/en unknown
2018
- 2018-06-06 JP JP2018108835A patent/JP2018168162A/ja active Pending
- 2018-09-13 US US16/129,851 patent/US11020480B2/en active Active
2019
- 2019-07-17 CY CY20191100762T patent/CY1121838T1/el unknown
2021
- 2021-05-27 US US17/331,674 patent/US11819548B2/en active Active
2023
- 2023-11-16 US US18/510,716 patent/US12653890B2/en active Active

Also Published As

Publication number	Publication date
CA3251146A1 (en)	2025-07-09
UA116007C2 (uk)	2018-01-25
CN105120897B (zh)	2017-12-05
EP2948179A1 (en)	2015-12-02
US20190008962A1 (en)	2019-01-10
WO2014114732A1 (en)	2014-07-31
US20150374818A1 (en)	2015-12-31
US20210283256A1 (en)	2021-09-16
US10098952B2 (en)	2018-10-16
KR102225239B1 (ko)	2021-03-09
TW201442726A (zh)	2014-11-16
US12653890B2 (en)	2026-06-16
AU2014209899A1 (en)	2015-07-23
SG11201505277VA (en)	2015-08-28
US20240100163A1 (en)	2024-03-28
JP2016505061A (ja)	2016-02-18
IL239767A0 (en)	2015-08-31
CN105120897A (zh)	2015-12-02
AR094577A1 (es)	2015-08-12
CA3179586C (en)	2025-07-08
EA201591378A1 (ru)	2016-04-29
ZA201505510B (en)	2016-12-21
MX2015009409A (es)	2016-03-16
JP6619231B2 (ja)	2019-12-11
CY1121838T1 (el)	2020-07-31
JP2018168162A (ja)	2018-11-01
RS59042B1 (sr)	2019-08-30
IL239767B (en)	2018-10-31
US11819548B2 (en)	2023-11-21
MX369664B (es)	2019-11-14
MA38318A1 (fr)	2017-02-28
KR20150108923A (ko)	2015-09-30
CA2897362A1 (en)	2014-07-31
KR102385193B1 (ko)	2022-04-12
EA034242B1 (ru)	2020-01-21
CA3179586A1 (en)	2014-07-31
HK1216609A1 (en)	2016-11-25
SI2948179T1 (sl)	2019-09-30
US11020480B2 (en)	2021-06-01
AU2014209899B2 (en)	2018-05-24
EP2948179B1 (en)	2019-06-19
CA2897362C (en)	2023-02-14
BR112015017490A2 (pt)	2017-07-11
KR20210027536A (ko)	2021-03-10

Publication	Publication Date	Title
IL273090B (en)	2022-06-01	Methods and preparations for the treatment of cancer
SI2948179T1 (sl)	2019-09-30	Sestavki, ki obsegajo nanodelce hafnij (IV) oksida ali renij (IV) oksida v kombinaciji z ionizirajočimi sevanji za zdravljenje raka
IL256874B (en)	2022-05-01	Immune checkpoint suppressors for use in the treatment of blood-borne cancers
IL245281A0 (en)	2016-06-30	Methods and preparations for the treatment of cancer
GB2516814B (en)	2016-08-31	Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
CL2015001985A1 (es)	2015-10-02	Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
IL244353A0 (en)	2016-04-21	Compounds and use for cancer treatment
HUE057901T2 (hu)	2022-06-28	Összetételek és módszerek rák kezelésére argininkiürítéssel és immunonkológiai szerekkel
ZA201506330B (en)	2016-10-26	Methods and compositions for treating leukemia
IL241555B (en)	2020-03-31	Preparations for the treatment of xerostomia and dental care
PT2968226T (pt)	2018-11-30	Composições de oxprenolol para tratamento do cancro
PL3082845T3 (pl)	2021-08-02	Sposoby i kompozycje do leczenia neuropatii obwodowych
PL2968478T3 (pl)	2019-01-31	Kompozycje i sposoby do leczenia karboksyhemoglobinemii
IL246065A0 (en)	2016-07-31	Valiprib in combination with carboplatin for the treatment of triple negative breast cancer
IL311363A (en)	2024-05-01	Preparations for use in the treatment of cognitive impairment
PL2941233T3 (pl)	2021-03-08	Kompozycje i sposoby leczenia chłoniaka z komórek t typu pierwotnie skórnego
HUE045407T2 (hu)	2019-12-30	Hafnium(IV)-oxid vagy rénium(IV)-oxid vagy nanorészecskéket tartalmazó készítmények ionizáló sugarakkal kombinálva, rák kezelésére
TWI561255B (en)	2016-12-11	Use of umirolimus and its derivatives for treating cancer
GB201302475D0 (en)	2013-03-27	Compositions and methods for treating biofilms
GB201302474D0 (en)	2013-03-27	Compositions and methods for treating biofilms
GB201302472D0 (en)	2013-03-27	Compositions and methods for treating biofilms
GB201322958D0 (en)	2014-02-12	Uses of oligouronates in cancer treatment
ITFI20130304A1 (it)	2015-06-25	Bicyclic peptidomimetics for use in the treatment of fungal infections